Evidence record · ER-SELANK-ANXIETY-021
Does Selank reduce anxiety symptoms?
Selank reduces anxiety symptoms in people with anxiety-spectrum conditions
Selank has small regional human studies reporting anxiety-related outcomes, but the evidence is insufficient for a dependable treatment conclusion. Limited samples, reporting constraints, combined regimens and weak independent replication prevent a reliable estimate of benefit or harm. The findings do not establish an online nasal product.
Claim boundary
What this verdict covers
The claim concerns clinically meaningful anxiety-symptom change in a defined condition. General calm, a biological signal and benefit in a combination regimen are not equivalent outcomes.
- Compound
- Selank
- Population
- Adults with anxiety-spectrum conditions
- Outcome
- Validated anxiety symptom change
- Record ID
- ER-SELANK-ANXIETY-021
Evidence synthesis
What the research can support
A small 2008 report and a later combination study provide human signals in anxiety-spectrum populations. They do not amount to a large, independently replicated, placebo-controlled development programme or establish comparative benefit against current treatments.
Why the confidence is low
The evidence is regionally concentrated, samples are small and methods are not reported at the level needed for a high-certainty estimate.
Decision boundary
What this record cannot tell you
This record cannot identify the contents, strength, purity, sterility or stability of a particular vial. It does not provide a dosing plan, administration instructions or a personal treatment recommendation. A supported narrow outcome cannot be transferred to a different route, population or product.
This publication has not independently tested a product for this record. Product evidence belongs to a named batch and method; clinical evidence belongs to the intervention actually studied.
From our work: how we checked this claim
ER-SELANK-ANXIETY-021 addresses one bounded question: Does Selank reduce anxiety symptoms?. Yianni Kiromitis checked the search record, source descriptions, study design, population, intervention identity, comparator and patient-important outcomes against the published evidence method. The source ledger contains 3 primary or official sources. Each was assigned only the proposition it can support; a regulatory document was not treated as a treatment trial, and an animal or laboratory finding was not presented as a dependable human outcome.
The recorded evidence basis is Limited human, the verdict is Insufficient and confidence is Low. Eleni Kiromitis reviewed study design, biomedical evidence, laboratory context and analytical limits. Dr Stavroula Nikitopoulou reviewed the clinical claim, adverse effects, contraindications, red flags and patient-facing safety wording. Both completed their assigned review on 10 August 2026. Yianni retained publication and correction responsibility. The review notes identify which source supports each material claim and which limitation must remain beside the conclusion.
No direct product testing, seller data, personal treatment experience or patient experience was used to set this verdict. The record cannot establish the contents, strength, purity, sterility or stability of a particular vial, and it does not provide dosing, administration or personalised treatment advice. A finding cannot be transferred to a different route, population, product or outcome without new evidence. We also checked the visible review date against the publication record and structured data. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.
Source ledger
Evidence used for this verdict
Each source supports only the proposition stated beside it. Regulatory scope and study scope remain visible.
| Source | What it establishes | What it does not establish | Checked |
|---|---|---|---|
| 2008 Selank clinical report | The study reports anxiety-related outcomes in a small human population. | It does not establish an independently replicated treatment programme. | 10 August 2026 |
| 2015 Selank combination study | The report examines Selank within a combined treatment strategy. | It cannot isolate broad effectiveness of Selank alone. | 10 August 2026 |
| FDA bulk-substance safety page | FDA identifies limited human safety information and peptide-quality concerns. | It does not quantify benefit or verify an online spray. | 10 August 2026 |
Quick answers
Frequently asked questions
What is the verdict on Selank for this claim?
The verdict is insufficient for the precise claim stated on this page. It combines the evidence type, directness, consistency and study limits; it is not a rating of the compound as a whole. The confidence field shows how readily new evidence could change the conclusion.
What evidence supports this verdict?
A small 2008 report and a later combination study provide human signals in anxiety-spectrum populations. They do not amount to a large, independently replicated, placebo-controlled development programme or establish comparative benefit against current treatments. The source ledger below links the primary or regulatory records used and states what each source cannot establish.
Does this evidence apply to a peptide vial sold online?
No. A study or authorisation applies to the exact material, formulation, route, population and controls that were evaluated. It cannot verify the identity, amount, purity, sterility, stability or delivery of a separate vial. Those are batch-specific product questions, not automatic extensions of an efficacy result.
Is Selank authorised in the UK for this use?
No UK marketing authorisation was identified for this use or for a medicine sold under this peptide name. The MHRA products database should be checked for the exact product and presentation. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
What should competitive athletes know?
Athletes should check the current WADA Prohibited List and obtain sport-specific advice. An experimental or non-approved peptide may fall within the S0 category even when it is not named individually. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
What could change this verdict?
Independent multicentre randomised trials with a credible placebo, validated symptom and function outcomes, adequate follow-up and complete adverse-event reporting. Any update would be dated and recorded through the site correction and version process. The boundary matters because evidence, authorisation and product quality answer different questions and should not be merged into one conclusion.
Continue the investigation